ArticleJournal of molecular histology2026
The possible role of astaxanthin in cisplatin-induced nephrotoxicity in rats: interplay between non-coding RNA, redox state, inflammation, and ferroptosis: a histological, immunohistochemical, and biochemical study.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is a broad-spectrum anticancer drug with considerable place among chemotherapeutic agents. However, its adverse effect as nephrotoxicity limits its clinical use. Astaxanthin is a marine carotenoid with potent antioxidant and anti-inflammatory activity. The current work investigated the biochemical and molecular mechanisms of cisplatin-induced nephrotoxicity and astaxanthin's capacity to mitigate it. Animals were assigned to four groups: control group, astaxanthin group (25 mg/Kg intraperitoneal (i.p)) for 8 days, cisplatin group (6 mg/Kg, i.p) on the 3rd day of the experiment, and astaxanthin-cisplatin group. Biochemical, molecular, and histopathological assessments were performed to assess renal injury. Cisplatin-induced nephrotoxicity was evident by the elevated levels of blood urea nitrogen (BUN), creatinine, and renal tissue malondialdehyde (MDA) and decreased levels of reduced glutathione (GSH) in renal tissue. The cisplatin group revealed a marked rise in the gene expression of metastasis-associated lung adenocarcinoma transcription-1 (MALAT-1) and nuclear factor kappa-B (NF-κB), along with a marked reduction in the gene expression of nuclear factor erythroid 2-related factor (Nrf2), glutathione peroxidase 4 (GPX4), and microRNA(miR)-146a. The cisplatin also induced disturbed renal architecture, including shrunken glomeruli and vacuolated tubular epithelium with small dense nuclei, in addition to edema and infiltration in-between the renal parenchyma. These changes were associated with a significant increase in the immune expression of NF-κB, desmin, and Bax in the renal parenchyma. Interestingly, co-administration of astaxanthin significantly attenuated nephrotoxicity indices, gene expression variations, and histopathological changes. Taken together, findings in the current research suggested that astaxanthin protects against cisplatin-induced nephrotoxicity by inhibiting oxidative stress, inflammation, and ferroptosis via MALAT-1and miR-146a/ NF-κB /Nrf2/GPX4 signaling pathway.
Indexed as
Identifiers
41559443What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.